A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML. Academic Article uri icon

Overview

publication date

  • March 6, 2025

Identity

Digital Object Identifier (DOI)

  • 10.1080/14796694.2025.2468578

PubMed ID

  • 40051275